Fields marked with an asterisk (*) are required!
General Terms and Conditions
Sample Preparation and Shipping Instructions
Journal for ImmunoTherapy of Cancer | Hermitte F.
Immunoscore® Colon analytical performance
Prognostic utility of immune markers and validation of Immunoscore® in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial [NCCTG N0147 (Alliance)]
Presentation of Immunoscore® Colon by Dr J Galon
Presentation of Immunoscore® Colon analytical performance by Fabienne Hermitte, PhD VP, R&D - Regulatory & Medical Affairs
• HalioDx received CMS CLIA Compliance for its laboratory based in Marseille
• Immunoscore® Colon, is now available to...
• For the first time, a tumor microenvironment immune gene signature associated with CAR T-cell treatment of non-Hodgkin...